国内创新药行业加速进入放量阶段,这5家药企在手现金均超过50亿

动脉网
Sep 05, 2025

国内Biotech创新药行业加速商业化,进入放量阶段。2025年上半年,69家A股、港股Biotech公司营收同比增长14%,达521.3亿元。其中,百济神州、信达生物、诺诚健华等五家药企在手现金均超过50亿元。百济神州上半年实现营收175.18亿元,同比增长46.03%,净利润扭亏为盈,主要得益于核心产品百悦泽®和百泽安®的全球销售表现。信达生物在手现金达95.4亿元,上半年营收59.53亿元,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10